<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">inovmed</journal-id><journal-title-group><journal-title xml:lang="ru">Инновационная медицина Кубани</journal-title><trans-title-group xml:lang="en"><trans-title>Innovative Medicine of Kuban</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2541-9897</issn><publisher><publisher-name>Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35401/2541-9897-2025-10-2-112-118</article-id><article-id custom-type="elpub" pub-id-type="custom">inovmed-1186</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СЛУЧАИ ИЗ КЛИНИЧЕСКОЙ ПРАКТИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE REPORTS</subject></subj-group></article-categories><title-group><article-title>Случай успешного хирургического лечения пациента с центральным плоскоклеточным раком легкого IIIB стадии из видеоторакоскопического доступа после неоадъювантной химиоиммунотерапии</article-title><trans-title-group xml:lang="en"><trans-title>Successful Video-Assisted Thoracoscopic Surgery Following Neoadjuvant Chemoimmunotherapy for Stage IIIB Central Squamous Cell Lung Cancer: A Case Report</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3966-0407</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зинченко</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Zinchenko</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зинченко Евгений Игоревич - к. м. н., доцент кафедры госпитальной хирургии, СПбГУ; врач-торакальный хирург, Центр торакальной хирургии, СЗОНКЦ им. Л.Г. Соколова.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Evgenii I. Zinchenko - Cand. Sci. (Med.), Associate Professor at the Hospital Surgery Department, Saint Petersburg State University; Thoracic Surgeon, Thoracic Surgery Center, Sokolov North-western District Research and Clinical Center.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8422-1342</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петров Андрей Сергеевич - к. м. н., доцент кафедры госпитальной хирургии, СПбГУ; врач-торакальный хирург, Центр торакальной хирургии, СЗОНКЦ им. Л.Г. Соколова.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Andrey S. Petrov - Cand. Sci. (Med.), Associate Professor at the Hospital Surgery Department, Saint Petersburg State University; Thoracic Surgeon, Thoracic Surgery Center, Sokolov North-western District Research and Clinical Center.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-7647-1759</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фатеева</surname><given-names>Д. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Fateeva</surname><given-names>D. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фатеева Дарья Леонидовна - ординатор по специальности «Торакальная хирургия», кафедра госпитальной хирургии.</p><p>199034, Санкт-Петербург, Университетская наб., 7–9</p></bio><bio xml:lang="en"><p>Daria L. Fateeva - Thoracic Surgery Resident, Hospital Surgery Department, Saint Petersburg State University.</p><p>Universitetskaya naberezhnaya 7-9, Saint Petersburg, 199034</p></bio><email xlink:type="simple">daria.l.fateeva@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9602-0908</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пищик</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Pischik</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пищик Вадим Григорьевич - д. м. н., профессор кафедры госпитальной хирургии, СПбГУ; руководитель Центра торакальной хирургии, СЗОНКЦ им. Л.Г. Соколова; главный хирург, ГКОД; главный внештатный специалист-торакальный хирург, Комитет по здравоохранению Санкт-Петербурга.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Vadim G. Pischik - Dr. Sci. (Med.), Professor at the Hospital Surgery Department, Saint Petersburg State University; Head of the Thoracic Surgery Center, Sokolov Northwestern District Research and Clinical Center; Chief Surgeon, City Clinical Oncology Dispensary; Chief Nonstaff Thoracic Surgeon, Health Committee of St. Petersburg.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный университет; Северо-Западный окружной научно-клинический центр им. Л.Г. Соколова Федерального медико-биологического агентства России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University; Sokolov Northwestern District Research and Clinical Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный университет; Северо-Западный окружной научно-клинический центр им. Л.Г. Соколова Федерального медико-биологического агентства России; Городской клинический онкологический диспансер; Комитет по здравоохранению Санкт-Петербурга</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University; Sokolov Northwestern District Research and Clinical Center; City Clinical Oncological Dispensary; Health Committee of St. Petersburg</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>06</month><year>2025</year></pub-date><volume>10</volume><issue>2</issue><fpage>112</fpage><lpage>118</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зинченко Е.И., Петров А.С., Фатеева Д.Л., Пищик В.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Зинченко Е.И., Петров А.С., Фатеева Д.Л., Пищик В.Г.</copyright-holder><copyright-holder xml:lang="en">Zinchenko E.I., Petrov A.S., Fateeva D.L., Pischik V.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.innovmedkub.ru/jour/article/view/1186">https://www.innovmedkub.ru/jour/article/view/1186</self-uri><abstract><p>У пациентов с IIIA–IIIB стадиями немелкоклеточного рака легкого в случаях, когда использование хирургического метода ограничено, улучшить отдаленные результаты позволяет комбинированное лечение: химиотерапия в неоадъювантном режиме с целью уменьшения размера опухоли с последующей возможностью радикального хирургического лечения.</p><p>В последние годы стандартная индукционная химиотерапия может дополняться иммунотерапией чек-поинт-ингибиторами, что активно обсуждается в современном научном сообществе. В то время как в одних публикациях демонстрируется эффективность неоадъювантной химиоиммунотерапии, другие авторы отмечают дополнительные трудности при оперативном вмешательстве после данного вида индукционного лечения.</p><p>В представленном нами клиническом наблюдении продемонстрированы особенности хирургического лечения пациента с центральным немелкоклеточным раком легкого IIIB стадии после химиоиммунотерапии; обсуждаются трудности, связанные с оперативным вмешательством при выполнении сложной анатомической резекции легкого из малотравматичного видеоторакоскопического доступа, а также рассматриваются способы профилактики интра- и послеоперационных осложнений.</p></abstract><trans-abstract xml:lang="en"><p>When surgical treatment is limited in patients with stage IIIA-IIIB non–small cell lung cancer (NSCLC), multimodality treatment can improve long-term outcomes: neoadjuvant chemotherapy to reduce the tumor size followed by radical surgery.</p><p>In recent years, the combination of standard induction chemotherapy with immune checkpoint inhibitors has been the subject of active debate in the literature. Some studies demonstrate the efficacy of neoadjuvant chemoimmunotherapy, whereas other authors note additional difficulties of surgery after it.</p><p>In this case report we demonstrate features of surgery in a male patient with stage IIIB central NSCLC after chemoimmunotherapy and discuss difficulties of surgery associated with a minimally invasive video-assisted thoracoscopic surgery approach in complex anatomical lung resection and methods for preventing intraoperative and postoperative complications.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>неоадъювантная химиоиммунотерапия</kwd><kwd>немелкоклеточный рак легкого</kwd><kwd>лечение немелкоклеточного рака легкого III стадии</kwd><kwd>хирургическое лечение немелкоклеточного рака легкого</kwd><kwd>видеоторакоскопический доступ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>neoadjuvant chemoimmunotherapy</kwd><kwd>non–small cell lung cancer</kwd><kwd>stage III NSCLC treatment</kwd><kwd>surgery for NSCLC</kwd><kwd>video-assisted thoracoscopic surgery</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chemical Biology Letters. 2023;10(1):451.</mixed-citation><mixed-citation xml:lang="en">Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chemical Biology Letters. 2023;10(1):451.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bade BC, Dela Cruz CS. Lung Cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1–24. PMID: 32008623. https://doi.org/10.1016/j.ccm.2019.10.001</mixed-citation><mixed-citation xml:lang="en">Bade BC, Dela Cruz CS. Lung Cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1–24. PMID: 32008623. https://doi.org/10.1016/j.ccm.2019.10.001</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hoy H, Lynch T, Beck M. Surgical treatment of lung cancer. Crit Care Nurs Clin North Am. 2019;31(3):303–313. PMID: 31351552. https://doi.org/10.1016/j.cnc.2019.05.002</mixed-citation><mixed-citation xml:lang="en">Hoy H, Lynch T, Beck M. Surgical treatment of lung cancer. Crit Care Nurs Clin North Am. 2019;31(3):303–313. PMID: 31351552. https://doi.org/10.1016/j.cnc.2019.05.002</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Girard N, Perol M, Simon G, et al. Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort. Lung Cancer. 2021;162:119–127. PMID: 34775215. https://doi.org/10.1016/j.lungcan.2021.10.017</mixed-citation><mixed-citation xml:lang="en">Girard N, Perol M, Simon G, et al. Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort. Lung Cancer. 2021;162:119–127. PMID: 34775215. https://doi.org/10.1016/j.lungcan.2021.10.017</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Provencio M, Serna-Blasco R, Nadal E, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40(25):2924–2933. Published correction appears in J Clin Oncol. 2022;40(32):3785. PMID: 35576508. PMCID: PMC9426809. https://doi.org/10.1200/JCO.21.02660</mixed-citation><mixed-citation xml:lang="en">Provencio M, Serna-Blasco R, Nadal E, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40(25):2924–2933. Published correction appears in J Clin Oncol. 2022;40(32):3785. PMID: 35576508. PMCID: PMC9426809. https://doi.org/10.1200/JCO.21.02660</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Forde PM, Spicer J, Lu S, et al; CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985. PMID: 35403841. PMCID: PMC9844511. https://doi.org/10.1056/NEJMoa2202170</mixed-citation><mixed-citation xml:lang="en">Forde PM, Spicer J, Lu S, et al; CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985. PMID: 35403841. PMCID: PMC9844511. https://doi.org/10.1056/NEJMoa2202170</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158(1):269–276. PMID: 30718052. PMCID: PMC6653596. https://doi.org/10.1016/j.jtcvs.2018.11.124</mixed-citation><mixed-citation xml:lang="en">Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158(1):269–276. PMID: 30718052. PMCID: PMC6653596. https://doi.org/10.1016/j.jtcvs.2018.11.124</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tong BC, Gu L, Wang X, et al. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022;163(2):427–436. PMID: 33985811. https://doi.org/10.1016/j.jtcvs.2021.02.099</mixed-citation><mixed-citation xml:lang="en">Tong BC, Gu L, Wang X, et al. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022;163(2):427–436. PMID: 33985811. https://doi.org/10.1016/j.jtcvs.2021.02.099</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao R, Guan X, Zhang P, et al. Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature. J Cancer Res Clin Oncol. 2024;150(4):175. PMID: 38573518. PMCID: PMC10995031. https://doi.org/10.1007/s00432-024-05683-9</mixed-citation><mixed-citation xml:lang="en">Zhao R, Guan X, Zhang P, et al. Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature. J Cancer Res Clin Oncol. 2024;150(4):175. PMID: 38573518. PMCID: PMC10995031. https://doi.org/10.1007/s00432-024-05683-9</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Петров А.С., Атюков М.А., Жемчугова О.А., Земцова И.Ю., Янчий М.Н., Яблонский П.К. Случай успешного лечения плоскоклеточного рака правого легкого IIIA стадии (иммунотерапия+хирургическое лечение), с последующей расширенной видеоторакоскопической сегментэктомией S6 по поводу метахронного рака левого легкого IА стадии. Вопросы онкологии. 2020;66(3):291–295. https://doi.org/10.37469/0507-3758-2020-66-3-291-295</mixed-citation><mixed-citation xml:lang="en">Petrov AS, Atyukov MA, Zhemchugova OA, Zemtsova IJu, Yanchii MN, Yablonskiy PK. Case of successfull treatment of squamous-cell carcinoma IIIA (immunotherapy+surgical resection), followed by VATS S6 segmentectomy for metachronous squamous-cell carcinoma IA in contralateral lung. Problems in Oncology. 2020;66(3):291–295. (In Russ.). https://doi.org/10.37469/0507-3758-2020-66-3-291-295</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Franzi S, Mattioni G, Rijavec E, Croci GA, Tosi D. Neoadjuvant chemo-immunotherapy for locally advanced non-small-cell lung cancer: a review of the literature. J Clin Med. 2022;11(9):2629. PMID: 35566754. PMCID: PMC9099888. https://doi.org/10.3390/jcm11092629</mixed-citation><mixed-citation xml:lang="en">Franzi S, Mattioni G, Rijavec E, Croci GA, Tosi D. Neoadjuvant chemo-immunotherapy for locally advanced non-small-cell lung cancer: a review of the literature. J Clin Med. 2022;11(9):2629. PMID: 35566754. PMCID: PMC9099888. https://doi.org/10.3390/jcm11092629</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">El Husseini K, Piton N, De Marchi M, et al. Lung cancer surgery after treatment with anti-PD1/PD-L1 immunotherapy for non-small-cell lung cancer: a case-cohort study. Cancers (Basel). 2021;13(19):4915. PMID: 34638399. PMCID: PMC8508022. https://doi.org/10.3390/cancers13194915</mixed-citation><mixed-citation xml:lang="en">El Husseini K, Piton N, De Marchi M, et al. Lung cancer surgery after treatment with anti-PD1/PD-L1 immunotherapy for non-small-cell lung cancer: a case-cohort study. Cancers (Basel). 2021;13(19):4915. PMID: 34638399. PMCID: PMC8508022. https://doi.org/10.3390/cancers13194915</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cao C, Guo A, Chen C, Zielinski R, Bott M. Neoadjuvant immunotherapy for patients with non-small cell lung cancer-current evidence. Ann Transl Med. 2020;8(22):1476. PMID: 33313221. PMCID: PMC7729370. https://doi.org/10.21037/atm-20-5026</mixed-citation><mixed-citation xml:lang="en">Cao C, Guo A, Chen C, Zielinski R, Bott M. Neoadjuvant immunotherapy for patients with non-small cell lung cancer-current evidence. Ann Transl Med. 2020;8(22):1476. PMID: 33313221. PMCID: PMC7729370. https://doi.org/10.21037/atm-20-5026</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">O’Brien M, Paz-Ares L, Marreaud S, et al; EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/ KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274–1286. PMID: 36108662. https://doi.org/10.1016/S1470-2045(22)00518-6</mixed-citation><mixed-citation xml:lang="en">O’Brien M, Paz-Ares L, Marreaud S, et al; EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/ KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274–1286. PMID: 36108662. https://doi.org/10.1016/S1470-2045(22)00518-6</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Brunelli A, Salati M, Rocco G, et al; ESTS Database Committee. European risk models for morbidity (EuroLung1) and mortality (EuroLung2) to predict outcome following anatomic lung resections: an analysis from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg. 2017;51(3):490–497. Published correction appears in Eur J Cardiothorac Surg. 2017;51(6):1212. PMID: 27744321. https://doi.org/10.1093/ejcts/ezw319</mixed-citation><mixed-citation xml:lang="en">Brunelli A, Salati M, Rocco G, et al; ESTS Database Committee. European risk models for morbidity (EuroLung1) and mortality (EuroLung2) to predict outcome following anatomic lung resections: an analysis from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg. 2017;51(3):490–497. Published correction appears in Eur J Cardiothorac Surg. 2017;51(6):1212. PMID: 27744321. https://doi.org/10.1093/ejcts/ezw319</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
